• info@icbcongress.com
• English
• Persian

• Login

Create Free Account

INTERNATIONAL CONGRESS OF

CancerGenetics

• Diagnostic value of HOXB-AS1 in breast cancer: a promising regulator of key signaling pathways

• Morteza Talebi Gharamaleki,¹ Ali Ghorbani,² Sheyda Farhadi,³ Mohammad Ahmadvand,^4,* seyyed mohammad kahani,⁵ Mir Salar Kahaei,⁶
  1. Department of Medical Genetics and Molecular Biology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran
  2. Iranian Biological resources center, Tehran, Iran
  3. Department of microbiology, Higher Education Institute of Rab-Rashid, Tabriz, Iran
  4. Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Hematology and Cell Therapy, Research Institute for Oncology, Tehran University of Medical Sciences, Tehran, Iran
  5. Department of Medical Genetics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
  6. Department of Medical Genetics, Mashhad university Medical Sciences, Mashhad, Iran
  
  
  
• Introduction: Antisense long non-coding RNAs (AS-lncRNAs) are transcribed from the opposite DNA strands of coding or non-coding genes and play crucial roles in cancer development and progression. AS-lncRNAs can either inhibit or promote tumor growth and metastasis, influencing gene expression regulation at both nucleic and cytoplasmic levels through cis and trans mechanisms. Aberrant AS-lncRNA expression in cancer cells is linked to alterations in various signaling pathways, making them promising targets for cancer research and potential clinical applications. The HOXB cluster antisense RNA 1 (HOXB-AS1), located on chromosome 17, has been associated with several cancers, including glioblastoma and endometrial cancer. This study aims to investigate the expression and role of HOXB-AS1 in breast cancer (BC), given its potential as a therapeutic target or biomarker.
• Methods: We conducted an in-silico analysis of HOXB-AS1 expression using microarray data from the GEO database, followed by experimental validation using BC and normal tissue samples from Iranian patients. RNA was extracted, and quantitative real-time PCR (qPCR) was performed to measure HOXB-AS1 expression. Results were verified with data from The Cancer Genome Atlas (TCGA). Differentially expressed genes (DE genes) were identified, and their correlation with HOXB-AS1 was analyzed. Additionally, protein-protein interaction (PPI) networks and hub genes were explored using bioinformatics tools.
• Results: qPCR results showed a significant downregulation of HOXB-AS1 in BC tissues compared to normal tissues. TCGA data corroborated these findings. Lower HOXB-AS1 levels were associated with decreased relapse-free survival (RFS) but not overall survival (OS) in BC patients. Receiver Operating Characteristic (ROC) curve analysis indicated that HOXB-AS1 could serve as a diagnostic marker for BC. Correlation and pathway analyses revealed that HOXB-AS1 expression negatively correlated with several oncogenic genes, suggesting its potential role as a tumor suppressor.
• Conclusion: HOXB-AS1 is significantly downregulated in breast cancer tissues, and its reduced expression is linked to poorer relapse-free survival. These findings suggest that HOXB-AS1 might function as a tumor suppressor in BC and highlight its potential as a diagnostic biomarker. Further research is needed to fully elucidate its role and therapeutic applicability in breast cancer.
• Keywords: Antisense RNAs Breast cancer noncoding RNA Bioinformatics Biomarker